Literature DB >> 9869232

Carcinoma of the tonsillar fossa: prognostic factors and long-term therapy outcome.

C A Perez1, M M Patel, K S Chao, J R Simpson, D Sessions, G J Spector, B Haughey, M A Lockett.   

Abstract

PURPOSE: To identify prognostic parameters and evaluate the therapeutic outcomes for patients with carcinoma of the tonsillar fossa treated with three treatment modalities. METHODS AND MATERIALS: The results of therapy are reported in 384 patients with histologically proven epidermoid carcinoma of the tonsillar fossa; 154 were treated with irradiation alone (55-70 Gy), 144 with preoperative radiation therapy (20-40 Gy), and 86 with postoperative irradiation (50-60 Gy). The operation in all but four patients in the last two groups consisted of an en bloc radical tonsillectomy with ipsilateral lymph node dissection.
RESULTS: Treatment modality and total irradiation doses had no impact on survival. Actuarial 10-year disease-free survival rates were 65% for patients with T1 tumors, 60% for T2, 60% for T3, and 30% for T4 disease. Patients with no cervical lymphadenopathy or with a small metastatic lymph node (N1) had better disease-free survival (60% and 70%, respectively) at 5 years than those with large or fixed lymph nodes (30%). Primary tumor recurrence (local, marginal) rates in the T1, T2, and T3 groups were 20-25% in patients treated with irradiation and surgery and 31% for those treated with irradiation alone (difference not statistically significant). In patients with T4 disease treated with surgery and postoperative irradiation, the local failure rate was 32% compared with 86% with low-dose preoperative irradiation and 47% with irradiation alone (p = 0.03). The overall recurrence rates in the neck were 10% for N0 patients, 25% for N1 and N2, and 35-40% for patients with N3 cervical lymph nodes, without significant differences among the various treatment groups. The incidence of contralateral neck recurrences was 8% with the various treatment modalities. On multivariate analysis the only significant factors for local tumor control and disease-free survival were T and N stage (p = 0.04-0.001). Fatal complications were noted in 7 of 144 (5%) patients treated with preoperative irradiation and surgery, 2 of 86 (2%) of those receiving postoperative irradiation, and 2 of 154 (1.3%) patients treated with radiation therapy alone. Other moderate or severe nonfatal sequelae were noted in 30% of the patients treated with preoperative irradiation and surgery, in 53% treated with postoperative irradiation, and in 19% receiving radiation therapy alone.
CONCLUSION: Primary tumor and neck node stage are the only significant prognostic factors influencing locoregional tumor control and disease-free survival. Treatment modality had no significant impact on outcome. Radiation therapy remains the treatment of choice for patients with stage T1-T2 carcinoma of the tonsillar fossa. In patients with T3-T4 tumors and good general condition, combination surgery and postoperative irradiation offers better tumor control than single-modality and preoperative irradiation procedures, but with greater morbidity.

Entities:  

Mesh:

Year:  1998        PMID: 9869232     DOI: 10.1016/s0360-3016(98)00291-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  9 in total

1.  Radiotherapy alone or combined with chemotherapy as definitive treatment for squamous cell carcinoma of the tonsil.

Authors:  William R Kennedy; Michael P Herman; Rohan L Deraniyagala; Robert J Amdur; John W Werning; Peter Dziegielewski; Jessica Kirwan; Christopher G Morris; William M Mendenhall
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-08       Impact factor: 2.503

2.  Squamous cell carcinoma of the tonsil managed by conventional surgery and postoperative radiation.

Authors:  Rahmatullah Rahmati; Snjezana Dogan; Owen Pyke; Frank Palmer; Mahmoud Awad; Nancy Lee; Dennis H Kraus; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Head Neck       Date:  2014-06-19       Impact factor: 3.147

3.  Retrospective analysis of the treatment results for patients with squamous cell carcinoma of tonsil.

Authors:  Ah Ram Chang; Hong-Gyun Wu; Charn Il Park; Kwang-Hyun Kim; Myung-Whun Sung; Dae-Seog Heo
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

4.  Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.

Authors:  Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-14       Impact factor: 7.038

5.  Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors.

Authors:  Valentina Krstevska; Igor Stojkovski; Beti Zafirova-Ivanovska
Journal:  Radiat Oncol       Date:  2012-05-28       Impact factor: 3.481

6.  Results of transoral laser microsurgery in 102 patients with squamous cell carcinoma of the tonsil.

Authors:  Martin Canis; Alexios Martin; Martina Kron; Alexandra Konstantinou; Friedrich Ihler; Hendrik A Wolff; Christoph Matthias; Wolfgang Steiner
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-29       Impact factor: 2.503

7.  Additional parameters to improve the prognostic value of the 8th edition of the UICC classification for human papillomavirus-related oropharyngeal tumors.

Authors:  Jos M J A A Straetmans; Marijn Stuut; Martin Lacko; Frank Hoebers; Ernst-Jan M Speel; Bernd Kremer
Journal:  Head Neck       Date:  2022-05-17       Impact factor: 3.821

8.  Long-term results of ipsilateral radiotherapy for tonsil cancer.

Authors:  Tae Ryool Koo; Hong-Gyun Wu
Journal:  Radiat Oncol J       Date:  2013-06-30

9.  Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study.

Authors:  Sanghyuk Song; Hong-Gyun Wu; Chang Geol Lee; Ki Chang Keum; Mi Sun Kim; Yong Chan Ahn; Dongryul Oh; Hyo Jung Park; Sang-Wook Lee; Geumju Park; Sung Ho Moon; Kwan Ho Cho; Yeon-Sil Kim; Yongkyun Won; Young-Taek Oh; Won-Taek Kim; Jae-Uk Jeong
Journal:  BMC Cancer       Date:  2017-08-30       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.